Dr. William Hunter has been a member of Correvio’s Board of Directors since 2007 and served as the Company’s President and CEO from 2012 to 2019. In January 2019, Dr. Hunter resigned as President but remained as CEO. During his tenure at Correvio, the Company grew from 8 employees to 140, increased revenues from $100,000 to $28M annually, acquired 6 hospital products and launched 5 of them through its own direct sales force in Europe. Prior to Correvio, Dr. Hunter co-founded and served as President and Chief Executive Officer of Angiotech Pharmaceuticals (1992-2011). After founding Angiotech while still in medical school in 1992, he grew the Company to become a profitable, diversified, device company with over 1,400 employees, several thousand commercially available products, and 12 facilities in 5 countries. Dr. Hunter currently also serves as President and CEO of Canary Medical, a company that utilizes implanted sensor, battery and transmission technology to create “smart” implanted medical devices that can “self-report” on function, activity, wear, complications and patient outcomes for up to 20 years. Dr. Hunter currently serves as a director of Rex Bionics Plc, SummatiX Plc and Adherium Plc. Dr. Hunter received his BSc from McGill University and his MSc and MD from the University of British Columbia. Dr. Hunter has also served as a practicing physician in British Columbia and has over 200 patents and patent applications to his name.

By following this link you will be leaving the correvio.com website. Please note that Correvio does not take responsibility for the content displayed on other websites: